For the Inventor, By the Inventor

Enter assignee name

Culver City, CA, United States of America

Nantcell, Inc.

USPTO Granted Patents = 49

CIPO Patents = 1

EPO Patents = 7

Trademarks = 2

Forward Citations = 34

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

Patrick Soon-Shiong (25 out of 476 patents)

Kayvan R Niazi (22 out of 101 patents)

Shahrooz Rabizadeh (15 out of 86 patents)

4. Hans G Klingemann (6 out of 47 patents)

5. Stephen Charles Benz (5 out of 57 patents)

6. Laurent H Boissel (5 out of 36 patents)

7. John H Lee (4 out of 13 patents)

8. Barry J Simon (4 out of 18 patents)

9. Mustafa Jaber (4 out of 22 patents)

10. Nicholas James Witchey (4 out of 160 patents)

11. Bing Song (3 out of 79 patents)

12. Jeffrey Safrit (3 out of 5 patents)

13. Christopher W Szeto (3 out of 14 patents)

14. Liudmila A Beziaeva (3 out of 11 patents)

15. Aaron Randolph Bassett (3 out of 4 patents)

Core Competencies:

Microbiome Analysis

Artificial Intelligence

Nant Cancer Vaccine

T-Cell Memory

Neoepitope Vaccines

Electroporation

HIV Treatment

Immunosuppressed Subjects

Personalized Therapeutics

Virus Particle Production

Tumor Evaluation

BCG Treatment

49 patents: Sort by Forward Citations

1. 12737880 - Systems and methods of analyzing microbiomes using artificial intelligence (2026-09-15),

2. 12734216 - TREATMENT OF IMMUNOSUPPRESSED SUBJECTS (2026-09-15),

3. 12730579 - Object storage and access management systems and methods (2026-09-08),

4. 12653874 - Nant cancer vaccine (2026-06-16),

5. 12580056 - Production and delivery tracking and sample verification of patient-specific therapeutics (2026-03-17),

6. 12571003 - Electroporation with active compensation (2026-03-10),

7. 12527865 - haNK cetuximab combinations and methods (2026-01-20),

8. 12491201 - Maximizing T-cell memory and compositions and methods therefor (2025-12-09),

9. 12427184 - Treatment of immunosuppressed subjects (2025-09-30),

10. 12311018 - Targeted neoepitope vectors and methods therefor (2025-05-27),

11. 12303552 - Treatment of immunosuppressed subjects (2025-05-20),

12. 12303477 - HIV treatment compositions and methods (2025-05-20),

13. 12297247 - Fusion molecules of CTLA4 and IL-15 (2025-05-13),

14. 12285481 - Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid protein (2025-04-29),

15. 12285480 - Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses (2025-04-29),

Company Overview

Nantcell, Inc., based in Culver City, CA, specializes in innovative therapeutic solutions targeting various health challenges. The company focuses on advanced T-cell memory technologies and patient-specific therapeutics, particularly in the realms of immunosuppressed treatment and HIV. Nantcell is also engaged in developing neoepitope vectors and COVID-19 therapeutics, leveraging deep learning models to enhance treatment efficacy. Their research encompasses the use of Bacillus Calmette-Guerin, positioning them at the forefront of personalized medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

49 Patents

#10 in Culver City, CA

#1,682 in California

#7,142 in US

#14,277 in the World

Culver City, CA, United States of America

Nantcell, Inc.

Forward Citations = 34

35 inventors:

Patrick Soon-Shiong (25 out of 476 patents)

Kayvan R Niazi (22 out of 101 patents)

Shahrooz Rabizadeh (15 out of 86 patents)

4. Hans G Klingemann (6 out of 47 patents)

5. Stephen Charles Benz (5 out of 57 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nantcell, Inc.. Retrieved from https://idiyas.com/company/nantcell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…